AstraZeneca PLC reported on 30 October that third-quarter Revenue rose 7% to $16,209m and kept its full-year guidance unchanged. The results closed a busy month of regulatory approvals and deal-making for the drugmaker.

What happened

AstraZeneca (LSE:AZN) is a constituent of the FTSE All-Share index and sits in the healthcare sector, among general drug manufacturers. According to an AI-generated summary on, third-quarter core Earnings Per Share rose 17% to $2.79. The full announcement text was not available on that page, so divisional figures are not given here.

For the first nine months of 2026, the same summary put total revenue at $46,881m, up 7%, with core earnings per share up 14% to $8.00. It did not say whether these growth rates are at constant exchange rates, so they should be read with that caveat.

Full-year guidance was reconfirmed: revenue growth in the mid-to-high single digits and low double-digit growth in core earnings per share. The most recent company items since then are routine, namely total voting rights and an admission of further securities on 2 November.

Why it matters for investors

The nine-month core earnings growth of 14% runs ahead of the low double-digit full-year guide, while revenue growth of 7% falls within the guided range. In our analysis, the question for the fourth quarter is whether that gap holds, rather than whether guidance changes.

The pipeline is where much of the longer-term debate sits. The summary cited 47 approvals in major regions since the fourth-quarter 2025 results, including four new medicines. It also cited 12 positive Phase III readouts, with combined peak revenue potential above $10bn. That revenue figure is a company estimate of potential, not a forecast of sales.

October's announcements added to that record. Enhertu was approved in the EU for HER2-positive early breast cancer on 27 October, and Ultomiris was approved in the US for IgA nephropathy on 22 October, according to 's announcement list.

Capital is also being put to work outside the company. AstraZeneca completed an Equity Investment in Summit Therapeutics on 5 October, described in the results summary as a $2bn investment, and an headline from 2 October also pointed to a Datroway collaboration with Summit involving Daiichi Sankyo. StockAnalysis listed a separate AI drug discovery deal with insitro around 15 October, worth up to $1.5bn with $40m upfront.

How the shares have performed

The latest price retrieved predates the results: 12,620p on 21 October 2026, on delayed data from StockAnalysis, broadly flat on the day. That sat within a 52-week range of 10,524p to 15,732p, so readers should check a live quote for the reaction to the results.

At that date the page showed a Market Capitalisation of about £195.7bn, a trailing price-to-earnings ratio of 25.06 and a forward ratio of 15.61. The Dividend Yield was shown as 1.89%, with the last ex-dividend date listed as 6 August 2026.

The same page recorded a consensus Buy rating from 24 analysts, with an average target of 15,794p, about 25% above that price. This is a third-party view and may not reflect the latest results.

What to watch next

Annual results are the next scheduled milestone, although a date was not confirmed in the material retrieved. Investors will test delivery against the reconfirmed guidance and the $10bn peak potential claim.

In the nearer term, attention is likely to fall on data presented at medical meetings. StockAnalysis listed company news around 19 October about overall survival data from four Phase III trials for ESMO 2026. Those readouts, and uptake of newly approved indications, will be the practical test of the pipeline case.